New European guideline on lowering cholesterol: as low as possible?
NEW ON THE MARKET
Sublingual immunotherapy of tree pollen allergy with ITULAZAX
THERAPY FROM A CRITICAL VIEWPOINT
Tranexamic acid (e.g. CYKLOKAPRON) after traumatic brain injury?
a-t READERS QUESTIONS AND COMMENTS
Sacubitril plus valsartan (ENTRESTO) for initial treatment of heart failure?
50 YEARS arznei-telegramm
50 years drug information – start of the a-t in turbulent times
arznei-telegramm from within – who we are and how we work
Drugs through the ages – from small molecules to complex biologics
Not optimal yet – trials and approval decisions
Drug risks – recognise early and prevent
A matter of price – how much may a drug cost?
Belittling and misleading advertising – a permanent threat
Drug quality – further positive or worsening?
Antiphospholipid syndrome – once again increased risk of thromboembolism with rivaroxaban (XARELTO)
Flurbiprofen lozenges in France available only on prescription
Policies on conflicts of interest are missing at medical schools free article
CURRENT ADR NETWORK REPORT
Neuropsychiatric adverse effects with montelucast (SINGULAIR, generics)
Tofacitinib (XELJANZ): caution in case of increased risk of thromboembolism
Vaginal rings for contraception – generics break more often
e a-t ON THE INTERNET
Mail order – potency drugs contain overdoses in some cases
Supplier does not want a black triangle for CARIBAN
Methocarbamol (ORTOTON, generics) against back pain – addendum: erroneous publication corrected